Bain SC, Hansen BB, Hunt B, Chubb B, Valentine WL
The rats received doses of KBP-089 (KBP) (0.625, 1.25 and 2.5 g/kg sc), liraglutide (L) (200 and 400 g/kg sc) and the combinations (KBP 0.625 + L 200 g/kg, KBP 0.625 + L 400 g/kg, KBP 1.25 + L 200 g/kg, KBP 1.25 + L 400 g/kg and KBP 2.5 + L 200 g/kg, KBP 2.5 + L 400 g/kg) and vehicle (saline) for 9 weeks
Both vial and pen formulations should never be frozen, as ice crystal formation can damage the medication's molecular structure and render it ineffective
None are currently FDA-approved for T1D, but off-label prescribing has been rising sharply and the clinical data is starting to catch up
In the oral mucosa, the prognosis is dismal for patients with any type of malignant cell